Dalaroo increases global focus on Greenland with strong critical minerals results from its maiden sampling program at Blue ...
Structure Therapeutics (GPCR) just moved its obesity pipeline up a gear by kicking off a first in human Phase 1 trial for ACCG-2671, its oral amylin receptor agonist targeting metabolic disease. See ...
Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral small molecule therapeutics to treat various chronic diseases with unmet medical needs ...
A research team has developed a hierarchical-shell perovskite nanocrystal technology that simultaneously overcomes the ...